Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05565742 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
NCT05565742: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT05565742 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 320 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (141% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05565742, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.
Primary Outcome
LPa levels were assessed using Immuno turbidimetric method. Percent change is calculated as: Percent Change=\[(Lp(a) at Time Point-Lp(a) at Baseline)/Lp(a) at Baseline\]×100 Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with log(Lp(a)) - log(Baseline) = log(Baseline) + Treatment + Time + Treatment\*Time (Type III sum of squares) as post-baseline measures. Result presented is after back-transformation. Variance-Covariance structure = Unstructured. Analyse
Interventions
- DRUG Placebo
- DRUG LY3819469
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2022-10-20 |
| Est. Completion | 2024-10-17 |
| Phase | Phase 2 |
What the finished NCT05565742 record still lists
NCT05565742 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (141% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05565742 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05565742 about?
NCT05565742 is a clinical study titled "A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]". The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.
What is the current status of trial NCT05565742?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2022-10-20. Estimated completion is 2024-10-17.
What interventions are being tested in trial NCT05565742?
The interventions under investigation include: Placebo (DRUG), LY3819469 (DRUG).
Who is sponsoring clinical trial NCT05565742?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05565742's enrollment target sits among peer trials
320 152nd of 2000 higher than 1,848 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI